RecruitingNCT03612726

The Overall Survival of Patients With Unresectable HCC in Real-life

The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region


Sponsor

Humanity & Health Medical Group Limited

Enrollment

5,000 participants

Start Date

Jul 16, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients with a diagnosis of unresectable hepatocellular carcinoma
  • Able to comprehend and provide written informed consent in accordance with institutional guidelines.

Exclusion Criteria1

  • Patients not willing to participate and/or give their written informed consent.

Locations(3)

Beijing 302 Hospital

Beijing, China

Humanity & Health Medical Group Limited

Hong Kong, Hong Kong

Tokyo University

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03612726


Related Trials